Financial Performance - Total revenue for the year 2023 reached HKD 129,304,000, an increase from HKD 119,894,000 in 2022, representing a growth of approximately 11.7%[20] - The company reported a net profit of HKD 38,490,000 for 2023, up from HKD 17,780,000 in the previous year, representing a growth of 116.5%[37] - Earnings per share for 2023 increased to HKD 1.00, compared to HKD 0.43 in 2022[37] - The total comprehensive income for the year was HKD 20,610,000, down from HKD 30,342,000 in the previous year, indicating a decrease of 32.20%[49] - The company reported a net profit before tax of HKD 25,385,000 for the year[44] Revenue Breakdown - Revenue from health-related products was HKD 37,791,000 in 2023, down from HKD 44,647,000 in 2022, indicating a decline of about 15.5%[20] - Revenue from new energy product procurement services was HKD 20,841,000 in 2023, with no revenue reported in 2022, marking a significant new revenue stream[20] - Healthcare-related business revenue increased to HKD 32,465,000 in 2023 from HKD 31,376,000 in 2022, showing a growth of 3.47%[45] - Trading business revenue decreased to HKD 116,442,000 in 2023 from HKD 126,759,000 in 2022, reflecting a decline of 8.39%[45] - Property-related business revenue surged to HKD 195,200,000 in 2023, up from HKD 130,914,000 in 2022, marking a significant increase of 49.00%[45] Asset and Liability Management - As of December 31, 2023, the group's non-current assets amounted to HKD 778.4 million, a decrease of HKD 10.8 million from HKD 789.2 million in 2022, primarily due to a reduction in fair value investments by HKD 27.1 million[1] - Current assets totaled HKD 918.8 million, down HKD 3.2 million from HKD 922.0 million in 2022, mainly due to a decrease in bank and cash balances by HKD 104.7 million[1] - The group's total assets, less current liabilities, amounted to HKD 1,473.2 million, compared to HKD 1,574.3 million in the previous year[10] - The total assets of the company were valued at HKD 1,254,321,000 in 2023, a decrease from HKD 1,327,085,000 in 2022[39] - The asset-liability ratio as of December 31, 2023, was 15.3%, up from 5.3% in 2022, with net debt of HKD 227.4 million compared to HKD 74.6 million in 2022[113] Cash Flow and Financing Activities - The net cash used in operating activities was HKD 136.5 million, primarily for the group's operational funding needs for the year ending December 31, 2023[5] - Net cash from financing activities was HKD 18.9 million, which included new bank loan proceeds of HKD 94.5 million and dividend payments of HKD 65.5 million[6] - The group's cash and cash equivalents totaled HKD 106.3 million as of December 31, 2023, down from HKD 211.0 million in 2022, with approximately 91.8% denominated in RMB[155] - The net cash generated from investment activities was HKD 53.7 million, primarily due to cash inflows from financial product investments of HKD 35.6 million and loan interest received of HKD 28.8 million[156] - As of December 31, 2023, the total bank loans of the group amounted to HKD 296.6 million, an increase of 21.8% from HKD 243.4 million in 2022[121] Operational Efficiency - The company incurred a total of HKD 14,496,000 in employee costs, including director remuneration, in 2023, down from HKD 18,851,000 in 2022, representing a decrease of about 23.0%[25] - The total operating expenses for 2023 were HKD 39.3 million, up from HKD 35.7 million in 2022, reflecting increased investment in business operations[70] - The company experienced a significant increase in other income and gains, reaching HKD 24.9 million in 2023, compared to a loss of HKD 3.7 million in 2022[70] - The company reported a rental income of HKD 17,104,000 in 2023, down from HKD 21,709,000 in 2022, indicating a decline of approximately 21.3%[20] - The company has a strong focus on expanding its international business, with plans to enhance brand depth and broaden distribution channels[68] Investment and Strategic Initiatives - The company is actively enhancing its clinical research capabilities in cell and gene therapy, aligning with new regulatory guidelines issued in September 2023[64] - The group has established strategic partnerships in the medical beauty sector, including collaborations with Lumenis and Peninsula, enhancing its product offerings[93] - The company launched the high-end health consumer brand AlpReleaf in Europe, which is now available in 22 countries[94] - The group is focusing on cell therapy and has made strategic investments in related high-tech enterprises[90] - The company plans to leverage technology and professional services to enhance health and beauty for more people, aligning with its corporate vision[36] Corporate Governance and Compliance - The company emphasizes the importance of good corporate governance for effective management and shareholder value enhancement[195] - The company has complied with the corporate governance principles as outlined in the listing rules[170] - The financial statements for the year ended December 31, 2023, have been audited and are consistent with the reported figures[172] - The company has adopted the standards set forth in Appendix C3 for its directors' securities trading behavior, confirming compliance as of December 31, 2023[196] - The annual performance announcement and annual report will be published at the shareholders' annual general meeting[198]
美瑞健康国际(02327) - 2023 - 年度业绩